Screener
ADMA Biologics ADMA Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from ADMA Biologics’s reported figures.
Based on the most recent quarter.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
FAQ
- What is ADMA Biologics's debt-to-equity?
- ADMA Biologics (ADMA) reported debt-to-equity of 0.5× in Q2 2026.
- How has ADMA Biologics's debt-to-equity changed year-over-year?
- ADMA Biologics's debt-to-equity increased by 1806.5% year-over-year, from 0× to 0.5×.
- What is the long-term trend for ADMA Biologics's debt-to-equity?
- Over 5 years (2020 to 2025), ADMA Biologics's debt-to-equity has grown at a -31.5% compound annual growth rate (CAGR), from 1.1× to 0.2×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about ADMA Biologics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude